This article was originally published in RAJ Devices
Chinese SFDA issues provisions for medical devices
You may also be interested in...
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.